# Who does Lilly (Eli) pay? Who are its key suppliers?
Canonical: https://valuechain.wiki/lilly-eli · Facet: suppliers · Updated: 2026-10-09T16:08:03.721+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Lilly (Eli)'s confirmed suppliers/cost counterparties include 에이비엘바이오, Incyte Corporation, AbCellera plus 3 undisclosed/aggregate relationships. Per the valuechain.wiki graph: 6 cost edges, backed by 10 dated sources, 3 of them primary filings (as of 2026-10-09).

### 에이비엘바이오 (high)  → /abl-bio.md
- metric: Amount 3,807,246,400,000원 · ABL 그랩바디-B 라이선스인 · Total KRW 3,807.2bn, upfront KRW 58.5bn
- note: A pipeline bet beyond incretins — Lilly licensed ABL Bio's Grabody-B blood-brain-barrier (BBB) shuttle platform for up to KRW 3,807.2bn (~$2.6B), with a KRW 58.5bn ($40M) upfront, to develop and commercialize multiple targets. It is a long-dated option to diversify an obesity-heavy revenue base into neuroscience and beyond.
- [confirms] DART (FSS) (KO, filing, published 2025-11-12) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20251112900144: "Total license value KRW 3,807,246,400,000 (USD 2,602m); upfront received on 6 Jan 2026"

### 제조 캐파 증설 (레바논 API·중국·미 신규 사이트) (high)
- metric: Amount $9B · 레바논 API 사이트
- note: Upfront investment where capacity is the revenue ceiling — the Lebanon, Indiana tirzepatide API site was raised from $3.7B to $9B (online end-2026), plus $3B in China and multiple new U.S. sites. Lilly lifted 2025 production capacity to 1.6x the prior year, and this capacity ramp effectively pre-commits future revenue. Separate lines are being built for oral orforglipron.
- [mentions] Medigate News (KO, news, published 2026-02-13) https://m.medigatenews.com/news/3176128778: "2025 capacity raised to 1.6x prior year, two new U.S. sites"
- [confirms] European Pharmaceutical Review (EN, news, published 2025-05-01) https://www.europeanpharmaceuticalreview.com/news/major-manufacturing-investment-to-support-api-production-for-tirzepatide/229480.article: "Lebanon API site raised from $3.7B to $9B (online end-2026)"
- [confirms] Fierce Pharma (EN, news, published 2025-04-01) https://www.fiercepharma.com/manufacturing/lilly-commits-3b-china-manufacturing-expansions-local-cdmo-partnerships: "$3B in China manufacturing, local CDMO partnerships"

### 인사이트 (high)  → /incyte.md
- metric: Amount $145M · FY2025 · Product royalty revenue from Lilly sales of OLUMIANT
- note: Lilly sells OLUMIANT in licensed territories and pays Incyte royalties based on net sales, from which Incyte recognized $144.6 million of OLUMIANT royalty revenue in FY2025.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-10) https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm: "Product royalty revenue related to Lilly net sales of OLUMIANT ... was $144.6 million."

### AbCellera (high)  → /abcellera.md
- note: AI antibody-discovery partner. COVID-19 antibodies (bamlanivimab, bebtelovimab) in 2020, expanded in July 2024 to multi-target immunology, cardiovascular and neuroscience work. Lilly pays upfront and research fees plus milestones and royalties; amounts undisclosed.
- [confirms] SEC EDGAR (AbCellera 10-K) (EN, filing, published 2026-02-24) https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm: "10-K partnership table: "Eli Lilly and Company Multi-target, multi-year Immunology, cardiovascular disease, and neuroscience July 31, 2024" and "Eli Lilly and Company Up to 9 targets, multi-year COVID-19 program and additional indications May 22, 2020"; bebtelovimab listed as marketed (EUA)."
- [confirms] AbCellera IR (EN, news, published 2024-07-31) https://investors.abcellera.com/news/news-releases/2024/AbCellera-and-Lilly-Expand-Collaboration-to-Develop-Antibody-Medicines/default.aspx: "Lilly expands its collaboration with AbCellera in immunology, cardiovascular disease and neuroscience; AbCellera receives an upfront and research payments plus milestones and royalties."
- [confirms] Medical Times (KO, news, published 2020-03-18) https://medicaltimes.com/Users/News/NewsView.html?ID=1132640: ""Eli Lilly and AbCellera signed a co-development agreement for antibody medicines ... on the 12th.""

### CDMO·충전 파트너 (비공개) (mid)
- note: An external buffer on the capacity ramp — the GLP-1 injectable bottleneck lies more in sterile fill-finish than in API, so Lilly uses external CDMO and fill-finish partners alongside its own buildout. Individual contracts are mostly undisclosed, but this outsourcing headroom is the lever that raises the near-term capacity ceiling.
- [mentions] Fierce Pharma (EN, news, published 2025-04-01) https://www.fiercepharma.com/manufacturing/lilly-commits-3b-china-manufacturing-expansions-local-cdmo-partnerships: "Local CDMO partnerships in China."

### 비바 시스템스 (mid)  → /veeva-systems.md
- note: Eli Lilly is an established large-pharma customer of Veeva and committed to a global Vault CRM rollout in 2026, while contract value and customer-specific revenue share were not disclosed.
- [confirms] Veeva Systems (EN, ir, published 2026-08-11) https://ir.veeva.com/news/news-details/2026/Veeva-Vault-CRM-Selected-by-Eli-Lilly-and-Company/default.aspx: "Lilly has committed to Veeva Vault CRM globally."
- [confirms] Samsung Securities (KO, research, published 2020-10-20) https://www.samsungpop.com/common.do?cmd=down&contentType=application/pdf&fileName=2010/2020102008124039K_01_04.pdf&saveKey=research.pdf: "The report identified Eli Lilly among Veeva Systems' large pharmaceutical customers."

### 웨스트 파마슈티컬 서비스 (mid)  → /west-pharmaceutical-services.md
- note: Eli Lilly purchases packaging materials for its weight-loss drugs from West, and West's revenue attributable to this customer has not been disclosed.
- [mentions] Maeil Business Newspaper (KO, news, published 2025-11-25) https://www.mk.co.kr/news/stock/11476244: "Its high-margin products are deeply integrated into customers' drug-development pipelines."
- [confirms] DBS Group Research (EN, research, published 2025-09-05) https://www.dbs.com/content/article/pdf/US_clover/West_Pharmaceutical_Services.pdf: "Novo Nordisk and Eli Lilly."

Reverse side: https://valuechain.wiki/lilly-eli/customers.md · Ripple: https://valuechain.wiki/lilly-eli/ripple.md

---
Full node: https://valuechain.wiki/lilly-eli.md · JSON: https://valuechain.wiki/lilly-eli.json